Company Overview
More
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
CEO： Xiangbin Huang
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
06833 Sinco Pharmaceuticals
1.6700.0000.00%
Closed 05/27 16:09 CCT
High
1.750
Open
1.660
Turnover
8.77M
Low
1.660
Pre Close
1.670
Volume
5.21M
Price Forecast
No Data
News
Comment
Sinco Pharmaceuticals: Annual Report 2021
Sinco Pharmaceuticals: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021 AND PROPOSED AMENDMENTS TO THE EXISTING M&A AND ADOPTION OF THE NEW M&A
Sinco Pharmaceuticals: DATE OF BOARD MEETING
Sinco Pharmaceuticals: 2021 INTERIM REPORT
Sinco Pharmaceuticals: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
Sinco Pharmaceuticals: DATE OF BOARD MEETING
Sinco Pharmaceuticals: POSITIVE PROFIT ALERT
Sinco Pharmaceuticals: Annual Report 2020
Sinco Pharmaceuticals: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020
Sinco Pharmaceuticals: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020